Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Lorenzo Livi


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


L. Livi1, G. Barletta2, F. Martella3, I. Desideri1, V. Scotti1, C. Becherini1, C. Saieva4, F. Terziani1, C. Bacci3, M. Airoldi5, G. Allegrini6, D. Amoroso7, F. Venditti2, R. Tarquini8, L. Orzalesi9, L. Sanchez9, M. Bernini9, J. Nori10, L. Fioretto3, I. Meattini1

Author affiliations

  • 1 Department Of Biomedical, Experimental, And Clinical Sciences, University of Florence, 50134 - Firenze/IT
  • 2 Cardiology Diagnostics - Cardiothoracic & Vascular, Azienda Ospedaliero Universitaria Careggi, Firenze/IT
  • 3 Soc Oncologia Medica, Azienda USL Toscana Centro, Firenze/IT
  • 4 Cancer Risk Factors And Lifestyle Epidemiology Unit, Institute for cancer research, prevention and clinical network (ISPRO), Firenze/IT
  • 5 2nd Medical Oncology Division, Department Of Oncology, AOU Città Della Salute e Della Scienza, 10126 - Torino/IT
  • 6 Oncologia, Dipartimento Oncologico - Azienda USL Toscana Nord Ovest, 57124 - Livorno/IT
  • 7 Medical Oncology, Ospedale Versilia USL12, 55041 - Lido di Camaiore/IT
  • 8 U.o.c Di Medicina Interna Internistica Ad Indirizzo Di Continuità, Ospedale San Giuseppe, Empoli/IT
  • 9 Breast Surgery Unit, Azienda Ospedaliero Universitaria Careggi, Firenze/IT
  • 10 Diagnostic Senology, Azienda Ospedaliero Universitaria Careggi, Firenze/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3613


SAFE trial (NCT2236806) is a phase 3 study comparing the effect on subclinical heart damage of bisoprolol (B), ramipril (R), or both drugs (R+B), as compared to placebo (P), in breast cancer treated with (neo)adjuvant anthracyclines +/- trastuzumab.


Primary endpoint is subclinical cardiotoxicity measured with echocardiography and global linear strain (GLS). This interim analysis was pre-specified on the first 120 patients who had completed cardiological assessments at 12-mos. Stopping rules per arm were: dose reduction >15%, study withdraw rate >5%, and no significant impact on 3D-left ventricular ejection fraction (3D-LVEF) as compared to T0 at 12-mos assessment.


A total of 191 out of 480 patients have been enrolled; overall 123 patients were available for the analysis (P = 34; R = 28; B = 31; R+B=30). 3D-LVEF decreased at 3-mos (-3.3%; p < 0.001), at 6-mos (-5.2%; p < 0.001) and at 12-mos (-3.7%; p = 0.004) respect to T0 in P; at 3-mos (-2.4%; p = 0.001), at 6-mos (-1.9%; p = 0.010), at 12-mos (-2.2%; p = 0.045) in R. In B and R+B patients no significant changes were observed at 3- and 12-mos, with a decrease at 6-mos (-2.5% and 3.0%, respectively; p = 0.002). Arm differences were significant (p = 0.038). GLS increased at 3-mos (5.7%; p < 0.001), at 6-mos (7.8%; p < 0.001) and at 12-mos (7.1%; p < 0.001) respect to T0 in P; at 3-mos (2.7%; p = 0.002), at 6-mos (3.2%; p = 0.014), but not at 12-mos in R; no significant changes at 3-mos, a significant increase at 6-mos (2.7%; p = 0.035), at 12-mos (3.2%; p = 0.008) in B; no significant changes at 3-, 6-, and 12-mos in R+B. Arm differences were significant (p = 0.002). Both R+B and the R arms showed a withdraw rate of 7%, with a dose reduction rates of 21% and 17%, respectively. R arm showed a significant decrease on 3D-LVEF at 12-mos as compared to T0 and will be evaluate for closure.


Following the stopping rules, the closure of the R arm is required and the study will continue with 3 arms. At the interim analysis, a cardioprevention strategy significantly impact on subclinical heart damage.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

University of Florence.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.